secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2023-07-05T23:59:59+00:00
Accession:  0001104659-23-078108
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics grants options for 1.05M shares to CEO and Interim CFO
--------------------------------------------------------------------------

- CEO Alexandra MacLean granted option to purchase 800,000 shares at $1.14/share.
- Interim CFO/COO David Jin granted option to purchase 250,000 shares at same price.
- Options vest in four equal annual installments beginning August 1, 2023.
- Options expire 10 years from grant dates (June 29, 2033 and June 30, 2033).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465923078108/0001104659-23-078108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465923078108/tm2320616d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-078108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer